Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures

Epilepsia

Volumn 40, Issue 1, 1999, Pages 74-82

  Dean, Christine ^a   Mosier, Michael ^b   Penry, Kiffin ^c  

^a Epilepsy Institute of North Carolina   (United States)

^b SANOFI   (France)

^c NONE

Author keywords

Add on therapy; Complex partial seizures; Epilepsy; Uncontrolled seizures; Vigabatrin

Indexed keywords

PLACEBO; VIGABATRIN;

ADULT; ARTICLE; CLINICAL TRIAL; COMPLEX PARTIAL SEIZURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EPILEPSY, COMPLEX PARTIAL; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; PLACEBOS; TREATMENT OUTCOME; VIGABATRIN;

EID: 0032947717     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb01991.x     Document Type: Article

References (23)

1. Duncan J. Medical factors affecting quality of life in patients with epilepsy. In: Round Table Series 23. London: Royal Society of Medicine; 1990:80-7.
2. Engel J. The epilepsies. In: Wyngaarden JB, Smith LH, Bennett JC, eds. Cecil textbook of medicine. 19th ed. Philadelphia: WB Saunders, 1992:2202-13.
3. Roberts E. Failure of GABAergic inhibition: a key to local and global seizures. Adv Neurol 1986;44:319-41.
4. Meldrum BS. GABAergic mechanisms in the pathogenesis and treatment of epilepsy. Br J Clin Pharmacol 1989;28(suppl 1):3-11.
5. Schechter PJ, Hanke NFJ, Grove J, Huebert N, Sjoerdsma A. Biochemical and clinical effects of γ-vinyl GABA in patients with epilepsy. Neurology 1984;34:182-6.
6. Grove J, Schechter PJ, Tell G, et al. Increased gamma-amino-butyric acid (GABA), homocarnosine and β-alanine in cerebrospinal fluid of fluid of patients treated with γ-vinyl GABA (4-amino-hex-5-enoic acid). Life Sci 1981;28:2431-9.
7. Reynolds EH. Gamma-vinyl GABA (vigabatrin): clinical experience in adult and adolescent patients with intractable epilepsy. Epilepsia 1992;33(suppl 5):S30-4.
8. Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991;41:889-926.
9. Rall TW, Schleifer LS. Drugs effective in the therapy of the epilepsies. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990:436-62.
10. Gibson JP, Yarrington JT, Loudy DE, Gerbig CG, Hurst GH. Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol 1990;18:225-38.
11. Peyster RG, Sussman NM, Hershey BL, et al. Use of ex vivo magnetic resonance imaging to detect onset of vigabatrin-induced intramyelinic edema in canine brain. Epilepsia 1995;36:93-100.
12. Jackson GD, Williams SR, Weller RO, et al. Vigabatrin-induced lesions in the rat brain demonstrated by quantitative magnetic resonance imaging. Epilepsy Res 1994;18:57-66.
13. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997;314:180-1.
14. Harding GFA. Severe persistent visual field constriction associated with vigabatrin: benefit/risk must be calculated for individual patients. BMJ 1998;316:232-3.
15. French JA, Mosier M, Walker S, Sommerville K, Sussman N. A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology 1996;46:54-61.
16. Mumford JP, Dam M. Meta-analysis of European placebo-controlled studies of vigabatrin in drug resistant epilepsy. Br J Clin Pharmacol 1989;27:101-7.
17. Sivenius MRJ, Ylinen A, Murros K, Matilainen R, Riekkinen P. Double-blind dose reduction study of vigabatrin in complex partial epilepsy. Epilepsia 1987;28:688-92.
18. Tartara A, Manni R, Galimberti CA, et al. Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy. Acta Neurol Scand 1992;86:247-51.
19. Sivenius J, Ylinen A, Murros K, Mumford JP, Riekkinen PJ. Vigabatrin in drug-resistant partial epilepsy: a 5-year follow-up study. Neurology 1991;41:562-5.
20. Sander J, Trevisol-Bittencourt PC, Hart YM, Shorvon SD. Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy. J Neurol Neurosurg Psychiatry 1990;53:1008-10.
21. Ben-Menachem E, Persson L, Mumford J. Long-term evaluation of once daily vigabatrin in drug-resistant partial epilepsy. Epilepsy Res 1990;5:240-6.
22. McGuire AM, Duncan JS, Trimble MR. Effects of vigabatrin on cognitive function and mood when used as add-on therapy in patients with intractable epilepsy. Epilepsia 1992;33:128-34.
23. Dijkstra JB, McGuire AM, Trimble MR. Effect of vigabatrin on cognitive function and mood. Hum Psychopharmacol 1992;7:319-23.